Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 11:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1099

Shown on this page

Current sort

Live official records

Conditions: HPV-related Lower Genital Tract Neoplasias, HPV-related Anal Neoplasias, Early Stage Lower Genital Tract Cancers
Interventions: Diagnostic tests for anal cancer screening; Diagnostic Test
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 35 Years and older · Female only
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 3
States / cities: New York, New York • Charleston, South Carolina • Houston, Texas

Conditions: Peripheral Arterial Hemorrhage, Trauma, GI Bleed, Ulcer, Hemorrhage
Interventions: Onyx™ Liquid Embolic System; Device
Lead sponsor: Medtronic Endovascular; Industry
Eligibility: 22 Years and older
Enrollment: 119 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Phoenix, Arizona • Irvine, California • Los Angeles, California + 17 more

Conditions: Advanced Heart Failure, Advanced Non-Colorectal Gastointestinal Cancer, Advanced Lung Cancer
Interventions: Tier-Palliative Care; Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: New York, New York

Conditions: Hidradenitis Suppurativa
Interventions: Remibrutinib; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 710 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 21
States / cities: Birmingham, Alabama • Fort Smith, Arkansas • North Little Rock, Arkansas + 17 more

Conditions: Respiratory Distress Syndrome, Pre-term Infants
Interventions: APC-0101 (SF-RI 1 surfactant for inhalation combined with a dedicated delivery system), Control; Combination Product · Other
Lead sponsor: Aerogen Pharma Limited; Industry
Eligibility: 1 Hour to 24 Hours
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 18
States / cities: Little Rock, Arkansas • La Jolla, California • Sacramento, California + 14 more

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions: Omecamtiv Mecarbil (OM), Placebo; Drug
Lead sponsor: Cytokinetics; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 1,800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 88
States / cities: Alexander City, Alabama • Birmingham, Alabama • Tucson, Arizona + 77 more

Conditions: Alopecia Areata
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 63 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 78
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Coronary Artery Disease, Coronary Artery Calcification
Interventions: Intravascular lithotripsy; Device
Lead sponsor: Bolt Medical; Industry
Eligibility: 18 Years and older
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 31
States / cities: La Jolla, California • Los Angeles, California • Riverside, California + 26 more

Conditions: Triple-Negative Breast Cancer
Interventions: Pembrolizumab, Sacituzumab tirumotecan, Capecitabine; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 1,530 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 93
States / cities: Mobile, Alabama • Chandler, Arizona • Fountain Valley, California + 78 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C); Drug
Lead sponsor: Kura Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 44
States / cities: Gilbert, Arizona • Clovis, California • La Jolla, California + 37 more

Conditions: Arterial Thromboembolism, Venous Thromboembolism, Pulmonary Embolism
Interventions: Prodigy Thrombectomy System, Symphony Thrombectomy System; Device
Lead sponsor: Imperative Care, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 12
States / cities: Huntsville, Alabama • Clearwater, Florida • Jacksonville, Florida + 9 more

Conditions: Cocaine Use Disorder, Cocaine Dependence, Substance Use Disorder (SUD), Opioid Use Disorder, Opioid Dependence
Interventions: Transcranial Direct Current Stimulator (tDCS), Cognitive Reappraisal Training; Device · Behavioral
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 60 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: New York, New York

About this Mount Sinai institution page

What this page lists: ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Mount Sinai

Filter and sort this campus

Live official records

Screening Women With Prior HPV for Anal Neoplasia

Onyx™ Liquid Embolic IDE Clinical Study

Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

Safety and Efficacy of APC-0101 in Preterm Infants With Respiratory Distress Syndrome

Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Modification of Coronary Calcium With Laser Based Intravascular Lithotripsy for Coronary Artery Disease (FRACTURE)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

Aspiration Thrombectomy Using the Symphony or Prodigy System

Transcranial Direct Current Stimulation (tDCS) for Treatment of Substance Use Disorder

About this Mount Sinai institution page